These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27449228)

  • 21. A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques.
    Liu X; Wang S; Chai L; Zhang D; Sun Y; Xu L; Sun J
    Int J Pharm; 2014 Jan; 461(1-2):529-39. PubMed ID: 24374219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability.
    Dennison TJ; Smith JC; Badhan RK; Mohammed AR
    Drug Des Devel Ther; 2017; 11():811-826. PubMed ID: 28352156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet.
    Aboelwafa AA; Basalious EB
    AAPS PharmSciTech; 2010 Sep; 11(3):1026-37. PubMed ID: 20532709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
    Kim S; Sharma VD; Lingineni K; Farhan N; Fang L; Zhao L; Brown JD; Cristofoletti R; Vozmediano V; Ait-Oudhia S; Lesko LJ; Trame MN; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1266-1274. PubMed ID: 31087554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
    Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
    Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
    Basu S; Yang H; Fang L; Gonzalez-Sales M; Zhao L; Trame MN; Lesko L; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1252-1263. PubMed ID: 31087553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet.
    Qin C; He W; Zhu C; Wu M; Jin Z; Zhang Q; Wang G; Yin L
    Int J Pharm; 2014 May; 466(1-2):276-85. PubMed ID: 24607209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.
    Gohel M; Bariya SH
    Pharm Dev Technol; 2009; 14(6):650-8. PubMed ID: 19883254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mini-tablets versus pellets as promising multiparticulate modified release delivery systems for highly soluble drugs.
    Gaber DM; Nafee N; Abdallah OY
    Int J Pharm; 2015 Jul; 488(1-2):86-94. PubMed ID: 25869450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
    Mitra A; Petek B; Bajc A; Velagapudi R; Legen I
    Eur J Pharm Biopharm; 2019 Jan; 134():117-125. PubMed ID: 30472143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation of venlafaxine for once daily administration using polymeric material hybrids.
    Ibrahim HK; Salah S
    J Microencapsul; 2016 Jun; 33(4):299-306. PubMed ID: 27121281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ghost-Pill-Buster: A Case Study of Intact Levetiracetam Extended-Release Tablets after Dissolution Testing.
    Sun D; Wen H; Externbrink A; Gao Z; Keire D; Krauss G; Jiang W
    CNS Drugs; 2016 May; 30(5):455-60. PubMed ID: 27048352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of hydrophilic matrix tablets based on Carbopol(®) 971P and low-viscosity sodium alginate for pH-independent controlled drug release.
    Al-Zoubi NM; AlKhatib HS; Obeidat WM
    Drug Dev Ind Pharm; 2011 Jul; 37(7):798-808. PubMed ID: 21247372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of hydrophilic, hydrophobic and waxy matrix excipients for sustained release tablets of venlafaxine hydrochloride.
    Yadav K; Yadav D; Srivastava AK
    Drug Dev Ind Pharm; 2013 Aug; 39(8):1197-206. PubMed ID: 22803761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation of a push-pull osmotic pump of felodipine solubilized by mesoporous silica nanoparticles with a core-shell structure.
    Wu C; Zhao Z; Zhao Y; Hao Y; Liu Y; Liu C
    Int J Pharm; 2014 Nov; 475(1-2):298-305. PubMed ID: 25148731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabrication of triple-layer matrix tablets of venlafaxine hydrochloride using xanthan gum.
    Gohel MC; Bariya SH
    AAPS PharmSciTech; 2009; 10(2):624-30. PubMed ID: 19444618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine.
    Scherf-Clavel M; Hommers L; Wurst C; Stonawski S; Deckert J; Domschke K; Unterecker S; Menke A
    J Psychopharmacol; 2020 Oct; 34(10):1105-1111. PubMed ID: 32669065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel subcutaneous infusion delivery system based on osmotic pump: in vitro and in vivo evaluation.
    Gong W; Ma R; Mei D; Jing P; Dong X; Li B; Yang Y; Du L; Mei XG; Hu FQ
    Drug Deliv; 2014 Feb; 21(1):1-7. PubMed ID: 24102136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network].
    Zhang ZH; Wang Y; Wu WF; Zhao X; Sun XC; Wang HQ
    Yao Xue Xue Bao; 2012 Dec; 47(12):1687-95. PubMed ID: 23460977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synchronous delivery of felodipine and metoprolol tartrate using monolithic osmotic pump technology.
    Zhao S; Yu F; Liu N; Di Z; Yan K; Liu Y; Li Y; Zhang H; Yang Y; Yang Z; Li Z; Mei X
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1723-31. PubMed ID: 27074758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.